Physician profile
Mark S Edwards
NPI 1760430284
$722.37
in general payments reported to CMS, 2019-2025
11 companies · $21.61 in 2025
The $21.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $63.56 · 2021: $179 · 2022: $99.84 · 2023: $34.30 · 2024: $28.52 · 2025: $21.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $84.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $84.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $133.39 | 2019-2023 | Ozempic, Rybelsus |
| Genentech USA, INC. | $130.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.92 | 2019-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.65 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $53.99 | 2019-2021 | |
| Lilly USA, LLC | $45.49 | 2020-2021 | |
| Pfizer INC. | $43.65 | 2020-2024 | |
| Allergan, INC. | $39.83 | 2019 | |
| Abbvie INC. | $39.07 | 2021-2022 | |
| Eisai INC. | $18.90 | 2021 | |
| Amarin Pharma, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.